Pharma — April 2024
-
Novartis' Fabhalta Demonstrates Significant Proteinuria Reduction In IgA Nephropathy Patients https://www.proinvestor.com/investornyt/1145265/novartis-fabhalta-demonstrates-significant-proteinuria-reduction-in-iga-nephropathy-patients
-
After Nearly A 20% Rise In Six Months Will Abbott Stock See Higher Levels Post Q1? https://www.proinvestor.com/investornyt/1145276/after-nearly-a-20-rise-in-six-months-will-abbott-stock-see-higher-levels-post-q1
-
Alvotech And Teva : FDA Approves Selarsdi Injection For Psoriasis And Psoriatic Arthritishttps://www.proinvestor.com/investornyt/1145923/alvotech-and-teva-fda-approves-selarsdi-injection-for-psoriasis-and-psoriatic-arthritis
-
Dagens aktie er Amgen Inc.
Amgen Inc. udvikler og fremstiller bioteknologi-baserede lægemidler og har fokus på områder med store udækkede medicinske behov.
Pioner inden for videnskaben om at bruge levende celler til at fremstille biologisk medicin. https://www.proinvestor.com/boards/119995/ -
Sandoz : Pyzchiva Approved In Europe For Gastroenterology, Dermatology, And Rheumatology Treatments https://www.proinvestor.com/investornyt/1148295/sandoz-pyzchiva-approved-in-europe-for-gastroenterology-dermatology-and-rheumatology-treatments
-
What's Next For Johnson & Johnson Stock After Beating Q1 Earnings? https://www.proinvestor.com/investornyt/1148302/whats-next-for-johnson-amp-johnson-stock-after-beating-q1-earnings
-
Vertex Pharma Obtains Exclusive License To TreeFrog's Cell Manufacturing Technology, C-Stem https://www.proinvestor.com/investornyt/1148845/vertex-pharma-obtains-exclusive-license-to-treefrogs-cell-manufacturing-technology-c-stem
-
Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia https://www.proinvestor.com/investornyt/1148849/sanofi-rilzabrutinib-luna-3-phase-3-study-meets-primary-endpoint-in-immune-thrombocytopenia
-
Novartis Q1 Profit Rises, Tops Estimates; Lifts FY24 View; Proposes Giovanni Caforio As New Chair https://www.proinvestor.com/investornyt/1148848/novartis-q1-profit-rises-tops-estimates-lifts-fy24-view-proposes-giovanni-caforio-as-new-chair
-
FDA Approves Novartis' Lutathera For Pediatric Gastroenteropancreatic Neuroendocrine Tumors https://www.proinvestor.com/investornyt/1149390/fda-approves-novartis-lutathera-for-pediatric-gastroenteropancreatic-neuroendocrine-tumors
-
ALK spås fortsat bedring i det europæiske tabletsalg af Jefferies https://www.proinvestor.com/investornyt/1149400/alk-spas-fortsat-bedring-i-det-europaeiske-tabletsalg-af-jefferies
-
Hanmi, Merck Collaborate To Evaluate BH3120 + Keytruda Combination In Metastatic Solid Tumors https://www.proinvestor.com/investornyt/1149381/hanmi-merck-collaborate-to-evaluate-bh3120-keytruda-combination-in-metastatic-solid-tumors
-
Will Higher Keytruda Sales Drive Merck's Q1 https://www.proinvestor.com/investornyt/1150001/will-higher-keytruda-sales-drive-mercks-q1
-
Astrazeneca stiger efter høj efterspørgsel på kræftmidler i første kvartal https://www.proinvestor.com/investornyt/1150060/astrazeneca-stiger-efter-hoj-eftersporgsel-pa-kraeftmidler-i-forste-kvartal
-
Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript https://www.proinvestor.com/investornyt/1150661/gilead-sciences-gild-q1-2024-earnings-call-transcript
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind